Buyer questions · Purchase decisions
For a 'sensitive skin' product on Tmall, how should we design our efficacy claims to avoid NMPA compliance risks?
Sensitive-skin claims require human efficacy evidence under NMPA regulations. The Tmall detail page is a statutory claim vehicle. The 'Cosmetics Supervision and Administration Regulations' mandate submitting human efficacy test or consumer usage test reports. Copy must remove all medical implications, retaining only compliant sensory descriptions. Ensure consistency across labels, details, and short videos. Failure to synchronize claims or match reports to final formulations risks rejection or delisting. Follow latest official texts.
1Human Evidence & Claim Boundaries
Claims of 'gentle, soothing, sensitive-skin' require human efficacy trials or consumer tests; in-vitro data is auxiliary only. Ban medical terms like 'pharmaceutical cosmetics' or 'anti-inflammatory'. Evidence must match the final production formula; any adjustment voids the report.
2Tmall Channel Compliance
Tmall detail pages, key visuals, and short-video scripts are all regulated. Claims must align with filed records. Platform audits follow NMPA rules; prohibited terms or exaggerated efficacy trigger delisting. Maintain a synchronized claim inventory across all channels to stay within approved filing scope.
3Document Consistency & Timing
Efficacy reports must be issued by qualified bodies with dates matching the formula version. Minor adjustments (e.g., fragrance ratio) without re-testing constitute false documentation. New ingredients or sensitive terms require timeline realignment; retroactive evidence is invalid. Follow latest official texts.
Follow-up questions
- Q:Can consumer usage tests fully replace human efficacy trials?
- A:No. Sensitive-skin claims require human-level evidence; consumer tests serve as primary or complementary proof, while in-vitro data is auxiliary only.
- Q:Are penalties applied if e-commerce details differ from packaging labels?
- A:Yes. All consumer-facing media are claim vehicles. Inconsistency may constitute false filing documentation, risking correction orders, fines, or delisting.
Updated 2026-09-18
Want this worked out for your category and target market? Send an inquiry